预约演示
更新于：2026-06-24
Beijing Mabworks Biotech Co., Ltd.
更新于：2026-06-24
概览
标签
肿瘤
免疫系统疾病
泌尿生殖系统疾病
单克隆抗体
双特异性抗体
ADC
疾病领域得分
一眼洞穿机构专注的疾病领域
技术平台
公司药物应用最多的技术
靶点
公司最常开发的靶点
关联
靶点 |
作用机制 |
在研机构 |
原研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段 |
首次获批国家/地区 |
首次获批日期 |
靶点 |
作用机制 |
在研机构 |
原研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段 |
首次获批国家/地区 |
首次获批日期 |
靶点 |
作用机制 |
在研机构 |
原研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段 |
首次获批国家/地区 |
首次获批日期 |
NCT07405970
A Phase 3 Clinical Study to Evaluate the Safety and Efficacy of Recombinant Humanized Monoclonal Antibody MIL62 Injection in the Treatment of Systemic Lupus Erythematosus.
NCT07375758
A Phase I/II, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy
NCT06232096
A Phase Ⅰ/Ⅱ Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of MBS314 Injection in Patients With Relapsed/Refractory Multiple Myeloma.
100 项与 北京天广实生物技术股份有限公司 相关的临床结果
登录后查看更多信息
登录后查看更多信息
2025-11-01Journal for ImmunoTherapy of Cancer
Oncolytic virus-induced IL-1β
+
monocyte-IL-6
+
CAF axis suppresses dendritic cell-mediated antitumor immunity in pancreatic cancer
Article
作者: Yu, Jufeng ; Wang, Jie ; Liu, Shiyu ; Zhang, Hongkai ; Han, Minghui ; Li, Fan ; Zhao, Zhigang ; Deng, Li ; Wang, Yi ; Wan, Yajuan ; Chen, Jingru ; Li, Yuanke ; Wang, Wei ; Li, Jiangmei ; Yang, Yi ; Wang, Han ; Zhang, Zhaoyuan ; Cao, Youjia ; Xu, Song ; Zhou, Feilong ; Ma, Wenxuan ; Zhao, Zhen
Background:
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a profoundly immunosuppressive tumor microenvironment, which features a dense desmoplastic stroma enriched with cancer-associated fibroblasts (CAFs) that collectively impede the efficacy of immunotherapies. Although oncolytic viruses (OVs) have demonstrated promising potential in eliciting antitumor immunity, the mechanisms by which stromal components modulate OV efficacy remain poorly understood.
Methods:
To investigate the interplay between immune and stromal components in PDAC following OV treatment, we employed murine and patient-derived tumor models. We characterized immune cell populations using single-cell RNA sequencing and flow cytometry. Functional studies included the engineering of a next-generation oncolytic herpes simplex virus expressing FLT3 ligand, OX40 ligand, and interleukin-12 (IL-12), combined with CD40 agonist antibodies to restore dendritic cell (DC) function and enhance T-cell responses.
Results:
We identified a novel immunosuppressive circuit wherein monocytes, sensing damage-associated molecular patterns and pathogen-associated molecular patterns from OV-infected tumor cells, secrete interleukin-1β. This, in turn, triggers IL-6 production by CAFs, creating an IL-6-rich milieu that impairs DC maturation and co-stimulatory signaling, thereby attenuating T cell-mediated antitumor immunity and restricting OV therapeutic efficacy. Importantly, combination therapy with the engineered OV and CD40 agonist antibodies restored DC functionality and elicited robust tumor-specific T-cell responses in both murine and patient-derived models.
Conclusion:
Our findings reveal a previously unrecognized monocyte-CAF-DC axis that mediates resistance to OV therapy through IL-1β and IL-6-driven suppression of DC function in PDAC. This study provides a mechanistically informed and translationally promising approach to overcome stromal immune suppression, restore effective antitumor immunity, and improve therapeutic outcomes for patients with PDAC.
2017-09-01Biotechnology letters4区 · 工程技术
Multi-parametric analysis reveals enhanced G2-phase arrest of an optimized anti-HER2 antibody to inhibit breast cancer
4区 · 工程技术
Article
作者: Lang, Xiaoling ; Lv, Ming ; Luo, Longlong ; Geng, Shusheng ; Li, Yan ; Geng, Jing ; Shen, Beifen ; Feng, Jiannan ; Qiao, Chunxia ; Li, Xinying
OBJECTIVES:
To find a "me-better" antibody by epitope-specific antibody optimization and multi-parametric analysis.
RESULTS:
Using epitope-specific library based on the commercial drug, Pertuzumab/2C4, we screened a novel human anti-HER2 antibody, MIL5, which has slightly higher affinity than the drug. MIL5 and 2C4 share the same epitope to bind HER2; however, MIL5 bound to HER2 His235-His245 more tightly than 2C4, which could be the main reason of its enhanced affinity. In vivo experiments also showed MIL5 had stronger anti-cancer activity than 2C4; however, the classical flow cytometry assays to detect cell apoptosis or cycling did not show convincing evidence of the advantages of MIL5. Thus we introduced the multi-parameter in-cell analysis method to evaluate the superiority of MIL5 to 2C4 in arresting cancer cells in G2-phase to inhibit cell growth and/or proliferation.
CONCLUSION:
Multi-parametric method confirmed stronger arrest of G2 by MIL5 to show better anti-cancer function both in vitro and in vivo than 2C4.
2016-03-09Science translational medicine1区 · 医学
Two-mAb cocktail protects macaques against the Makona variant of Ebola virus
1区 · 医学
Article
作者: Zhang, Boyan ; Luo, Longlong ; Bi, Shengli ; Fernando, Lisa ; He, Shihua ; Ippolito, Giuseppe ; Shen, Beifen ; Jacobs, Michael ; Qiu, Xiangguo ; Feng, Jiannan ; Zeitlin, Larry ; Ye, Pei ; Kobinger, Gary P. ; Audet, Jonathan ; Kroeker, Andrea ; Bovendo, Hugues Fausther ; Lv, Ming ; Wei, Haiyan ; Wong, Gary ; Li, Feng ; Gao, George F. ; Saphire, Erica Ollmann ; Bello, Alexander
A two–monoclonal antibody cocktail protects nonhuman primates against Ebola virus 3 days after lethal exposure.
2026-06-24
·微信
100 项与 北京天广实生物技术股份有限公司 相关的药物交易
登录后查看更多信息
100 项与 北京天广实生物技术股份有限公司 相关的转化医学
登录后查看更多信息
组织架构
使用我们的机构树数据加速您的研究。
登录
或
管线布局
2026年06月25日管线快照
管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期
药物发现
8
2
临床前
临床申请批准
1
6
临床1期
临床2期
6
1
批准上市
其他
11
登录后查看更多信息
当前项目
登录后查看更多信息
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
营收
使用 Synapse 探索超过 36 万个组织的财务状况。
登录
或
科研基金(NIH)
访问超过 200 万项资助和基金信息，以提升您的研究之旅。
登录
或
投资
深入了解从初创企业到成熟企业的最新公司投资动态。
登录
或
融资
发掘融资趋势以验证和推进您的投资机会。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用